Descriptions:
Bloomberg Tech sits down with Joe Lonsdale — Palantir co-founder and managing partner of venture firm 8VC — for a wide-ranging interview on the state of AI investment, US-China technology competition, and defense tech. The conversation opens with Lonsdale’s assessment of the AI race: he estimates the US is six to twelve months ahead of China in frontier model capability, and argues that in an environment where agent capabilities are doubling every few months, that gap is strategically decisive — particularly in cyber and defense applications.
Lonsdale is notably pointed on biotech IP theft, describing a pattern in which China has moved from a marginal position to capturing more than a third of new drug therapeutics globally, aided by an FDA approval process that Lonsdale says takes over 700 days for Phase 1 trials versus 90 days in some Chinese jurisdictions. He argues that AI is about to accelerate biotech dramatically — citing Orca Bio’s recent FDA approval for a safer bone marrow transplant protocol — making the competitive and security stakes higher.
On the investment side, Lonsdale announces that 8VC has closed its largest fund to date at $1.5 billion, roughly equivalent in effective deployment capacity to a $400-500M fund from a decade ago given today’s round sizes. About 30% of capital goes to companies the firm co-founds directly, including defense startup Saronic. Lonsdale also reflects on Palantir’s valuation crossing $300 billion and frames the current AI moment as a larger wave than the SaaS transition, with portfolio companies posting 5-10x growth.
📺 Source: Bloomberg Tech · Published July 13, 2026
🏷️ Format: Interview
